Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Pulmonary hypertension (PH) is present in over two-thirds of patients who experience heart failure with preserved ejection fraction (HFpEF), and it worsens their prognosis, particularly when combined with right ventricular dysfunction. Effective treatments for HFpEF-related PH are limited.
Case Summary: A 70-year-old woman presented with severe exertional dyspnea and hypoxia. Echocardiography revealed a preserved ejection fraction with advanced diastolic dysfunction, as well as severe PH. Right heart catheterization showed pulmonary pressures at systemic levels and elevated left-sided filling pressures. Significant symptom improvement and normalized pulmonary pressures were noted after treatment with sacubitril-valsartan and a sodium-glucose cotransporter 2 (SGLT2) inhibitor.
Discussion: Although sacubitril-valsartan and SGLT2 inhibitors have been proven effective in HFpEF, their specific role in HFpEF-PH remains unclear. This case highlights their potential to improve hemodynamics and symptoms in this challenging patient population.
Take-home Message: Sacubitril-valsartan and SGLT2 inhibitors may be effective for treating PH in HFpEF; further investigation is warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaccas.2025.104827 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction of Tricuspid Regurgitation in Pulmonary Arterial Hypertension.
JACC Case Rep
September 2025
Department of Cardiology, Monaldi Hospital, Naples, Italy. Electronic address:
Background: Pulmonary hypertension is a contraindication to correction of tricuspid regurgitation.
Case Summary: A 75-year-old Italian woman with previous episodes of right heart failure was diagnosed with World Health Organization (WHO) functional class IV pulmonary arterial hypertension (PAH) complicated by torrential tricuspid regurgitation. After 6 months of treatment with diuretic agents, macitentan, and tadalafil, she improved to WHO functional class III, with a pulmonary vascular resistance (PVR) decreasing from 5.
Real-World Adherence and Persistence of Upfront Therapy in Patients with Pulmonary Arterial Hypertension in the United States.
Pulm Ther
September 2025
Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA, USA.
Introduction: Pulmonary arterial hypertension (PAH) is a rare, progressive disease resulting from elevated pulmonary arterial pressure leading to right ventricular failure and death. Optimal adherence and persistence to medical therapy are necessary to improve outcomes. The objective of this study was to characterize adherence and persistence to first-line PAH therapies in patients newly initiating treatment.
View Article and Find Full Text PDFScreening for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia: when, how often and does it matter?
Arch Dis Child Fetal Neonatal Ed
September 2025
Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Objective: Bronchopulmonary dysplasia (BPD) associated pulmonary hypertension (BPD-PH) is the most severe endotype of BPD; there is insufficient evidence to support the optimal screening strategy in at-risk infants. We hypothesised that serial echocardiography throughout hospitalisation would improve PH detection with increased negative predictive value (NPV) beyond 36 week's postmenstrual age (PMA).
Study Design: This was a single centre cohort study conducted between 2017 and 2023.
Clinical impact of mean pulmonary arterial pressure after balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension.
Open Heart
September 2025
Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
Background: Balloon pulmonary angioplasty (BPA) improves haemodynamics in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Previous studies on BPA have set the treatment objective to achieve a mean pulmonary arterial pressure (mPAP) of <30 mm Hg. However, the clinical impact of mPAP after BPA remains unclear.
View Article and Find Full Text PDFFacilitating Earlier Diagnosis of Pulmonary Hypertension Using a Novel Noninvasive Diagnostic.
JACC Case Rep
September 2025
Atrium Health Navicent, Macon, Georgia, USA.
Background: Pulmonary hypertension (PH) is frequently underdiagnosed due to limitations of transthoracic echocardiography, particularly when tricuspid regurgitant velocity (TRV) is unmeasurable. CorVista PH (point-of-care test for pulmonary hypertension [POC-PH]) is a novel, Food and Drug Administration-cleared point-of-care diagnostic with 82% sensitivity and 92% specificity for identifying mean pulmonary artery pressure elevation.
Summary: We present a patient who underwent multiple transthoracic echocardiograms negative for PH.